ConductScience.org, home

Paper19251545

A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.

Sun HY and 5 others. J Formos Med Assoc, 2009. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. Papers, record 19251545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19251545

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.
PubMed
Journal
J Formos Med Assoc
PubMed
Year
2009
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
0.8
iCite
Revised in PubMed
2019-11-11
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sun HYHsin-Yun
2Chen YJYing-Jung
3Chen ILIn-Lon
4Gau CSChurn-Shiouh
5Chang SCShan-Chwen
6Luh KTKwen-Tay

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
HepatitisMajor topic
TuberculosisMajor topic
Adolescent
Adult
Aged
Aged, 80 and over
Causality
Comorbidity
Female
Humans
Incidence
Male
Middle Aged
Prospective Studies
Risk Factors
Taiwan
Young Adult

Source PubMed

Download CSV of topics

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in19933035Prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.https://conductscience.org/library/papers/19933035PubMed
Comment in22248841Hepatitis during antituberculosis treatment.https://conductscience.org/library/papers/22248841PubMed

Download CSV of comments and corrections

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
42809079HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/42809079PubMed
34698694Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection.J Chin Med Assoc2022https://conductscience.org/library/papers/34698694PubMed
29340497Tuberculosis treatment.J Bras Pneumol2017https://conductscience.org/library/papers/29340497PubMed
28224437Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis.J Huazhong Univ Sci Technolog Med Sci2017https://conductscience.org/library/papers/28224437PubMed
27516382Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clin Infect Dis2016https://conductscience.org/library/papers/27516382PubMed
26833347Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.BMC Infect Dis2016https://conductscience.org/library/papers/26833347PubMed
26767859Early monitoring for detection of antituberculous drug-induced hepatotoxicity.Korean J Intern Med2016https://conductscience.org/library/papers/26767859PubMed
26106962Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.Clinics (Sao Paulo)2015https://conductscience.org/library/papers/26106962PubMed
25595441Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.Tuberculosis (Edinb)2015https://conductscience.org/library/papers/25595441PubMed
25525805Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.PLoS One2014https://conductscience.org/library/papers/25525805PubMed
24897928The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study.BMC Infect Dis2014https://conductscience.org/library/papers/24897928PubMed
24292367Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.Lung2014https://conductscience.org/library/papers/24292367PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19251545

GET https://conductscience.org/api/papers/v1/19251545/authors